Work

A phase II clinical study of PD-1 inhibitor tislelizumab combined with chemotherapy for unresectable recurrent locally advanced nasopharyngeal carcinoma (RETICULA-NPC trial).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e18061

Authors: Xiaoshen Wang, Ye Zhang, Ruichen Li, Yang Zhao, Rui Yang

Institutions: Shanghai Medical College of Fudan University, Fudan University, Eye & ENT Hospital of Fudan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162690953

Cites:

Cited by:

Related to: